VYYRF (Voyageur Pharmaceuticals) ROCE %: -261.54% (As of Feb. 2026)

What is Voyageur Pharmaceuticals ROCE %?

Voyageur Pharmaceuticals VYYRF +7.71% 18 ROCE % is -261.54% as of Feb. 2026. GuruFocus rates VYYRF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Voyageur Pharmaceuticals's annualized ROCE % for the quarter that ended in Feb. 2026 was -261.54%.

Voyageur Pharmaceuticals (OTCPK:VYYRF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Voyageur Pharmaceuticals ROCE % Related Terms

Voyageur Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals ROCE % Chart

Voyageur Pharmaceuticals Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Nov24

Nov25

ROCE %

Get a 7-Day Free Trial

-178.34

-97.71

-92.34

-168.07

-393.12

Voyageur Pharmaceuticals Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Aug25	Nov25	Feb26
ROCE %	Get a 7-Day Free Trial															-372.64	-200.26	-424.45	-245.91	-261.54

18GF Score

Voyageur Pharmaceuticals Ltd VYYRF

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Voyageur Pharmaceuticals ROCE % Calculation

Voyageur Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Nov. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Nov. 2025 )		(A: Nov. 2024 )		(A: Nov. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Nov. 2025 )		(A: Nov. 2024 )		(A: Nov. 2025 )
	=	-2.514	/	( ( (1.859 - 1.499)	+	(2.209 - 1.29) )	/ 2 )
	=	-2.514	/	( (0.36	+	0.919)	/ 2 )
	=	-2.514	/	0.6395
	=	-393.12 %

Voyageur Pharmaceuticals's ROCE % of for the quarter that ended in Feb. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Feb. 2026 )		(Q: Nov. 2025 )		(Q: Feb. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Feb. 2026 )		(Q: Nov. 2025 )		(Q: Feb. 2026 )
	=	-1.836	/	( ( (2.209 - 1.29)	+	(2.161 - 1.676) )	/ 2 )
	=	-1.836	/	( ( 0.919	+	0.485 )	/ 2 )
	=	-1.836	/	0.702
	=	-261.54 %

(1) Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -261.54% mean?

Voyageur Pharmaceuticals (VYYRF) has a ROCE % of -261.54% as of Feb. 2026.

Is Voyageur Pharmaceuticals' ROCE % too high?

Voyageur Pharmaceuticals' current ROCE % is -261.54%. Overall, Voyageur Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.

How does Voyageur Pharmaceuticals' ROCE % compare to ZTS and UTHR?

Voyageur Pharmaceuticals' ROCE % of -261.54% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Voyageur Pharmaceuticals's current ROCE % is -261.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Voyageur Pharmaceuticals stock overvalued right now?

Voyageur Pharmaceuticals (VYYRF) has a current ROCE % of -261.54%. The current ROCE % is -261.54%. Voyageur Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current ROCE % is -261.54% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies XCNQ:MVMD XCNQ:FNT.U TSX:LABS TSXV:ROMJ XCNQ:GWAY XCNQ:TRIP XCNQ:OPTI XCNQ:IAN TSX:AVCN TSXV:MPH XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges VM:Canada

Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6

Website https://www.voyageurpharmaceuticals.ca

Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.

18GF Score

Get the complete analysis for VYYRF

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10

Price

View VYYRF Analysis

See ROCE % data for all stocks →